The 67th Annual Meeting of the American Society of Hematology (ASH) – the world's largest and most influential international academic event in the field of hematology – was held in Orlando, USA, from December 6 to 9. A rare case report titled "Diagnosis and Treatment of Marginal Zone B-Cell Lymphoma with Central Nervous System Involvement" by the team led by Chief Physician Wei Fang from the Department of Hematology, the First Affiliated Hospital of our university, was successfully selected for the meeting and published in BLOOD, a top-tier medical journal. This achievement provides valuable clinical insights for the global medical community to deepen its understanding of the diagnostic pathways and treatment strategies for this complex and rare lymphoma, demonstrating the hospital's solid foundation and innovative capabilities in the diagnosis and treatment of difficult and severe hematological diseases.

Lymphoma is renowned for its high clinical and biological heterogeneity. According to the World Health Organization (WHO) classification, it has more than 100 subtypes. Among these, numerous difficult and rare subtypes pose significant challenges to diagnosis and treatment. Particularly when lymphoma invades multiple organs throughout the body, the condition is often more critical. Therefore, the precise diagnosis and treatment of difficult and severe lymphoma have become a key benchmark for measuring the comprehensive strength of a hematology center.

As the Shanxi Provincial Center for the Diagnosis and Treatment of Critically Ill and Complex Patients, the First Affiliated Hospital of our university undertakes the diagnosis and treatment of complex hematological diseases for patients from Shanxi Province and surrounding regions. The Department of Hematology has always adhered to its patient-centered mission, focusing on the precise diagnosis and treatment innovation of difficult and severe hematological diseases. In response to ongoing medical needs, the department ensures the timely admission of patients with various complex hematological tumors by optimizing resource allocation and improving diagnosis and treatment efficiency. Meanwhile, the department persists in the integrated development of clinical practice and scientific research, conducting continuous research driven by practical clinical problems. In recent years, its rich experience in the field of difficult and severe diseases such as hematological tumors has been gradually transformed into high-quality research outputs. This year alone, the department has had 2 academic achievements selected by international top-tier academic conferences, indicating that the diagnostic and therapeutic capabilities as well as research level of the Department of Hematology in the field of hematological tumors have been recognized by international peers, steadily promoting the high-quality development of the discipline.